HomeInsightsStock Comparison

Ishita Drugs Industries Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Ishita Drugs Industries Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jul 20, 2025

Key Highlights

  • The Latest Trading Price of Ishita Drugs & Industries Ltd is ₹ 79.83 as of 18 Jul 15:30.
  • The P/E Ratio of Ishita Drugs & Industries Ltd is 0 as of March 2024 .The P/E Ratio of Remus Pharmaceuticals Ltd is 47.2 as of March 2024.
  • The Market Cap of Ishita Drugs & Industries Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024.
  • The revenue of Ishita Drugs & Industries Ltd for the Mar '25 is ₹ 4.72 crore as compare to the Dec '24 revenue of ₹ 4.2 crore. This represent the growth of 12.38% The revenue of Remus Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Ishita Drugs & Industries Ltd for the Mar '25 is ₹ 0.45 crore as compare to the Dec '24 ebitda of ₹ 0.36 crore. This represent the growth of 25% The ebitda of Remus Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Ishita Drugs & Industries Ltd changed from ₹ 0.14 crore to ₹ 0.29 crore over 8 quarters. This represents a CAGR of 43.92% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Ishita Drugs & Industries Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 3.5 % on March 2024 . This represents a CAGR of 16.93% over 2 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ishita Drugs & Industries Ltd

  • Ishita Drugs & Industries Limited was incorporated in Feb.'92 by Jagdish Agarwal.
  • The Company is engaged in the manufacture of various Activa Pharma Ingredients, drug intermediates, fine chemicals and excipient.
  • It has a state-of-art manufacturing facility, in terms of reaction capabilities, quality control and environmental safety.
  • The plant has been designed and constructed to meet GMP norms. The genesis of the Ishita Group in 1992 was the result of the entrepreneurial spirit of Mr. Jagdish Agrawal, who set up a reactive dye manufacturing unit in Ahmedabad.
  • Buoyed by the growth of its first Venture, the Group made its maiden foray in the pharma sector in 1981 by setting up a small Bulk drugs plant at Surendranagar in Gujarat, to cater to the need of Pharma industry for Quality Products.

About Remus Pharmaceuticals Ltd

  • Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
  • Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
  • It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
  • The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

Ishita Drugs & Industries Ltd News Hub

News

Ishita Drugs & Industries to hold board meeting

Ishita Drugs & Industries will hold a meeting of the Board of Directors of the Company on ...

Read more

11 Jun 2025 09:43

News

Ishita Drugs & Industries to table results

Ishita Drugs & Industries will hold a meeting of the Board of Directors of the Company on ...

Read more

24 May 2025 17:36

News

Ishita Drugs & Industries schedules board meeting

Ishita Drugs & Industries will hold a meeting of the Board of Directors of the Company on ...

Read more

07 Feb 2025 12:42

News

Ishita Drugs & Industries to conduct board meeting

Ishita Drugs & Industries will hold a meeting of the Board of Directors of the Company on ...

Read more

07 Nov 2024 14:30

News

Ishita Drugs & Industries AGM scheduled

Ishita Drugs & Industries announced that the Annual General Meeting (AGM) of the company w...

Read more

28 Aug 2024 12:11

News

Ishita Drugs & Industries to declare Quarterly Result

Ishita Drugs & Industries will hold a meeting of the Board of Directors of the Company on ...

Read more

10 Aug 2024 16:48

Remus Pharmaceuticals Ltd News Hub

News

Board of Remus Pharmaceuticals recommends final dividend

Remus Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

19 May 2025 09:57

News

Remus Pharmaceuticals to table results

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 17 M...

Read more

13 May 2025 16:52

News

Board of Remus Pharmaceuticals recommends interim dividend

Remus Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

09 Nov 2024 16:57

News

Remus Pharmaceuticals to convene board meeting

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 No...

Read more

07 Nov 2024 10:21

News

Remus Pharmaceuticals to convene AGM

Remus Pharmaceuticals announced that the 9th Annual General Meeting (AGM) of the company w...

Read more

31 Aug 2024 15:40

News

Remus Pharmaceuticals to table results

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 M...

Read more

10 May 2024 12:07

SWOT Analysis Of Remus Pharmaceuticals Ltd

Strength

4

S

Weakness

3

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Ishita Drugs & Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Remus Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ishita Drugs & Industries Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Ishita Drugs & Industries Ltd or Remus Pharmaceuticals Ltd?

Market cap of Ishita Drugs & Industries Ltd is 23 Cr while Market cap of Remus Pharmaceuticals Ltd is 1,153 Cr

What are the key factors driving the stock performance of Ishita Drugs & Industries Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Ishita Drugs & Industries Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ishita Drugs & Industries Ltd and Remus Pharmaceuticals Ltd?

As of July 20, 2025, the Ishita Drugs & Industries Ltd stock price is INR ₹79.83. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹978.75.

How do dividend payouts of Ishita Drugs & Industries Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Ishita Drugs & Industries Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions